A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)

DRUG: Gefapixant
DRUG: Placebo (for gefapixant)

PHASE2

Phase

COMPLETED

Status

Enrollment

INDUSTRY

Sponsor class

Conditions

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)